PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12016742::ACT015696

GI

Evidence text

Paper-level observation

StCl‐GI_GII + αPD‐1 treatment supported animal survival up to forty‐five days post‐tumor inoculation, a value significantly higher compared to treatment with PBS or TAAs + αPD‐1 (P < 0.0001 in both cases) (Figure 5e).
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
General Toxic
Measure
survival_rate
Comparator
<
Raw observation
P < 0.0001 vs PBS and TAAs + αPD-1
Normalized measurement
<0.0001
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Mus musculus
Assay method
Not reported by source
Sequence
EGSRNQDWL
Standardization
ready simple

Source publication

Off‐The‐Shelf Multivalent Nanoconjugate Cancer Vaccine Rescues Host Immune Response against Melanoma

Advanced Materials · 2025

DOI 10.1002/adma.202417348 PMC12016742
Parent mention

Related peptide identities

PEPDIA-PLP-000563

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.